RNA-seq data from upadacitinib (Janus kinase (JAK) 1 inhibitor) and risankizumab (IL-23 inhibitor) phase 2 CD clinical trials were used to support the clinical response to upadacitinib and risankizumab in IBD TNF-inadequate responders. This evidence concerns the gene TNF and inflammatory bowel disease.